U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Neuroendocrine Carcinoma

MedGen UID:
1719330
•Concept ID:
C5237419
•
Neoplastic Process

Definition

Neuroendocrine carcinoma that does not respond to treatment. [from NCI]

Professional guidelines

PubMed

Treatment of Aggressive Thyroid Cancer.
Huang J, Harris EJ, Lorch JH
Surg Pathol Clin 2019 Dec;12(4):943-950. doi: 10.1016/j.path.2019.08.004. PMID: 31672300
Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches.
Femia D, Prinzi N, Anichini A, Mortarini R, Nichetti F, Corti F, Torchio M, Peverelli G, Pagani F, Maurichi A, Mattavelli I, Milione M, Bedini N, Corti A, Di Bartolomeo M, de Braud F, Pusceddu S
Target Oncol 2018 Oct;13(5):567-582. doi: 10.1007/s11523-018-0585-y. PMID: 30073632
Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?
Rusinek D, Chmielik E, Krajewska J, Jarzab M, Oczko-Wojciechowska M, Czarniecka A, Jarzab B
Int J Mol Sci 2017 Aug 22;18(8) doi: 10.3390/ijms18081817. PMID: 28829399Free PMC Article

Recent clinical studies

Etiology

Metastatic rectal neuroendocrine carcinoma presenting with treatment-refractory immune thrombocytopenia: A case report and literature review.
Bancheno WM, Adidam SR, Melaku MA
Medicine (Baltimore) 2022 Jul 22;101(29):e29616. doi: 10.1097/MD.0000000000029616. PMID: 35866784Free PMC Article
Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, Antonelli A
Semin Cancer Biol 2022 Feb;79:180-196. Epub 2020 Nov 26 doi: 10.1016/j.semcancer.2020.11.013. PMID: 33249201
Treatment of Aggressive Thyroid Cancer.
Huang J, Harris EJ, Lorch JH
Surg Pathol Clin 2019 Dec;12(4):943-950. doi: 10.1016/j.path.2019.08.004. PMID: 31672300
Everolimus.
Hasskarl J
Recent Results Cancer Res 2018;211:101-123. doi: 10.1007/978-3-319-91442-8_8. PMID: 30069763
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P
Lancet Oncol 2016 Oct;17(10):1374-1385. Epub 2016 Sep 1 doi: 10.1016/S1470-2045(16)30364-3. PMID: 27592805Free PMC Article

Diagnosis

Peptide Receptor Radionuclide Therapy in Thyroid Cancer.
Gubbi S, Koch CA, Klubo-Gwiezdzinska J
Front Endocrinol (Lausanne) 2022;13:896287. Epub 2022 May 30 doi: 10.3389/fendo.2022.896287. PMID: 35712243Free PMC Article
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY
Eur Urol Oncol 2022 Dec;5(6):714-718. Epub 2022 Feb 23 doi: 10.1016/j.euo.2021.11.005. PMID: 35216942Free PMC Article
Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, Antonelli A
Semin Cancer Biol 2022 Feb;79:180-196. Epub 2020 Nov 26 doi: 10.1016/j.semcancer.2020.11.013. PMID: 33249201
DLL3: an emerging target in small cell lung cancer.
Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K
J Hematol Oncol 2019 Jun 18;12(1):61. doi: 10.1186/s13045-019-0745-2. PMID: 31215500Free PMC Article
Merkel cell carcinoma.
Becker JC, Stang A, DeCaprio JA, Cerroni L, Lebbé C, Veness M, Nghiem P
Nat Rev Dis Primers 2017 Oct 26;3:17077. doi: 10.1038/nrdp.2017.77. PMID: 29072302Free PMC Article

Therapy

TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY
Eur Urol Oncol 2022 Dec;5(6):714-718. Epub 2022 Feb 23 doi: 10.1016/j.euo.2021.11.005. PMID: 35216942Free PMC Article
Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, Antonelli A
Semin Cancer Biol 2022 Feb;79:180-196. Epub 2020 Nov 26 doi: 10.1016/j.semcancer.2020.11.013. PMID: 33249201
Immunotherapy for Non-melanoma Skin Cancer.
Shalhout SZ, Emerick KS, Kaufman HL, Miller DM
Curr Oncol Rep 2021 Aug 27;23(11):125. doi: 10.1007/s11912-021-01120-z. PMID: 34448958Free PMC Article
Treatment of Aggressive Thyroid Cancer.
Huang J, Harris EJ, Lorch JH
Surg Pathol Clin 2019 Dec;12(4):943-950. doi: 10.1016/j.path.2019.08.004. PMID: 31672300
DLL3: an emerging target in small cell lung cancer.
Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K
J Hematol Oncol 2019 Jun 18;12(1):61. doi: 10.1186/s13045-019-0745-2. PMID: 31215500Free PMC Article

Prognosis

Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, Antonelli A
Semin Cancer Biol 2022 Feb;79:180-196. Epub 2020 Nov 26 doi: 10.1016/j.semcancer.2020.11.013. PMID: 33249201
Treatment of Aggressive Thyroid Cancer.
Huang J, Harris EJ, Lorch JH
Surg Pathol Clin 2019 Dec;12(4):943-950. doi: 10.1016/j.path.2019.08.004. PMID: 31672300
Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma.
Saito Y, Muramatsu T, Kanai Y, Ojima H, Sukeda A, Hiraoka N, Arai E, Sugiyama Y, Matsuzaki J, Uchida R, Yoshikawa N, Furukawa R, Saito H
Cell Rep 2019 Apr 23;27(4):1265-1276.e4. doi: 10.1016/j.celrep.2019.03.088. PMID: 31018139
Merkel cell carcinoma.
Becker JC, Stang A, DeCaprio JA, Cerroni L, Lebbé C, Veness M, Nghiem P
Nat Rev Dis Primers 2017 Oct 26;3:17077. doi: 10.1038/nrdp.2017.77. PMID: 29072302Free PMC Article
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P
Lancet Oncol 2016 Oct;17(10):1374-1385. Epub 2016 Sep 1 doi: 10.1016/S1470-2045(16)30364-3. PMID: 27592805Free PMC Article

Clinical prediction guides

Aggressive pituitary tumors (PitNETs).
Nishioka H
Endocr J 2023 Mar 28;70(3):241-248. Epub 2023 Mar 3 doi: 10.1507/endocrj.EJ23-0007. PMID: 36858483
Immune checkpoint inhibitors to treat cutaneous malignancies.
Barrios DM, Do MH, Phillips GS, Postow MA, Akaike T, Nghiem P, Lacouture ME
J Am Acad Dermatol 2020 Nov;83(5):1239-1253. Epub 2020 May 24 doi: 10.1016/j.jaad.2020.03.131. PMID: 32461079Free PMC Article
Merkel Cell Carcinoma - Current Controversies and Future Directions.
Steven N, Lawton P, Poulsen M
Clin Oncol (R Coll Radiol) 2019 Nov;31(11):789-796. doi: 10.1016/j.clon.2019.08.012. PMID: 31594644
Aggressive variants of castration-resistant prostate cancer.
Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H, Logothetis C, Rubin MA
Clin Cancer Res 2014 Jun 1;20(11):2846-50. Epub 2014 Apr 11 doi: 10.1158/1078-0432.CCR-13-3309. PMID: 24727321Free PMC Article
Neuroendocrine transdifferentiation of prostate carcinoma cells and its prognostic significance.
Marcu M, Radu E, Sajin M
Rom J Morphol Embryol 2010;51(1):7-12. PMID: 20191113

Recent systematic reviews

Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review.
Maghsoomi Z, Emami Z, Malboosbaf R, Malek M, Khamseh ME
BMC Cancer 2021 May 20;21(1):579. doi: 10.1186/s12885-021-08257-x. PMID: 34016077Free PMC Article
Clinicopathological data and treatment modalities for pancreatic vipomas: a systematic review.
Schizas D, Mastoraki A, Bagias G, Patras R, Moris D, Lazaridis II, Arkadopoulos N, Felekouras E
J BUON 2019 Mar-Apr;24(2):415-423. PMID: 31127985
Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review.
Broder MS, Beenhouwer D, Strosberg JR, Neary MP, Cherepanov D
World J Gastroenterol 2015 Feb 14;21(6):1945-55. doi: 10.3748/wjg.v21.i6.1945. PMID: 25684964Free PMC Article
New therapeutic options for advanced forms of thyroid cancer.
Bernet V, Smallridge R
Expert Opin Emerg Drugs 2014 Jun;19(2):225-41. Epub 2014 Mar 3 doi: 10.1517/14728214.2014.894017. PMID: 24588376

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...